Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.antiviral.2020.104811 http://scihub22266oqcxt.onion/10.1016/j.antiviral.2020.104811 32360182!7188648!32360182     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32360182&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Antiviral+Res 2020 ; 179 (?): 104811 Nephropedia Template TP {{tp|p=32360182|t=2020. Antiviral activities of type I interferons to SARS-CoV-2 infection |pdf=|usr=}}{{32360182}} gab.com Text Antiviral activities of type I interferons to SARS-CoV-2 infection JO: Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=32360182 #FOAvip There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons alpha and beta (IFNalpha/beta). Treatment with IFN-alpha or IFN-beta at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC(50) of IFN-alpha and IFN-beta treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19. Twit Text FOAVip Antiviral activities of type I interferons to SARS-CoV-2 infection ????Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=32360182 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32360182 #FOAvip English Wikipedia <ref>{{Cite pmid|32360182}}</ref> Antiviral activities of type I interferons to SARS-CoV-2 infection #MMPMID32360182 Mantlo E; Bukreyeva N; Maruyama J; Paessler S; Huang C Antiviral Res 2020[Jul]; 179 (?): 104811 PMID32360182show ga There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons alpha and beta (IFNalpha/beta). Treatment with IFN-alpha or IFN-beta at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC(50) of IFN-alpha and IFN-beta treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19. |Animals[MESH] |Antiviral Agents/*pharmacology[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |Chlorocebus aethiops[MESH] |Coronavirus Infections/*drug therapy/immunology/virology[MESH] |Humans[MESH] |Immunity, Innate[MESH] |Interferon Type I/*pharmacology[MESH] |Interferon-alpha/pharmacology[MESH] |Interferon-beta/pharmacology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/immunology/virology[MESH] |Recombinant Proteins/pharmacology[MESH] |SARS-CoV-2[MESH] |Severe Acute Respiratory Syndrome/*drug therapy/immunology/virology[MESH] |Vero Cells[MESH] |Viral Load/drug effects[MESH]Antiviral activities of type I interferons to SARS-CoV-2 infection (epmc).pdf DeepDyve Pubget Overpricing